Notifications

CLECELL signed a joint business MoU to promote the commercialization of an anti-cancer drug sensitivity test with CancerFree Biotech 3D bioprinting company CLECELL announced that it had signed an MoU with Taiwanese bio company CancerFree Biotech for the commercialization of an organoid-based anti-cancer drug sensitivity test. Since its establishment in 2016, CLECELL had been exploring various applications leveraging its differentiated 3D bioprinting technology. Anti-cancer drug sensitivity test, the evaluation of the degree to which cancer cells respond to anti-cancer drugs, is one of the areas that the company has investigated. CancerFree Biotech, founded in Taiwan, has developed in vitro platform which tests the sensitivity of anti-cancer drugs by extracting a small amount of circulating tumor cells from the blood and culturing them to create a 3D organoid model. Based on this platform, the business tested the efficacy of anti-cancer medications on more than 1,000 patients along with 100 varieties of solid tumor cancer cells in Asia. CLECELL has planned to integrate the sensitivity evaluation technology of CancerFree with its product development and therefore provide medical facilities with better services. Additionally, the two companies will work together to develop a more sensitive evaluation model of cancer cells from patients and enter the global market afterward. The size of the cancer treatment market, worth $187 billion in 2021, and in vitro diagnostics, which exceeds 99 billion, made anti-cancer drug sensitivity services a promising market. “Anti-cancer drug sensitivity test is a field worthwhile to challenge not only as a profit model for the company but also as a mission to contribute to humanity by increasing the survival ratio of cancer patients through an accurate selection of anti-cancer drugs. In order to shorten the research and development period and build up an effective service model to test anti-cancer drugs, we are trying to cooperate with the 3rd parties in Korea as well as the global market,” said Kyoung Whee Jeon, the CEO of CLECELL.

* Date : October 5th (Wed) - 8th (Sat) 2022 * Location : ICC Jeju International Convention Center – Jeju Island The 3D bioprinter U-FAB ACTIVO was unveiled by Clecell at the 2022 TERMIS-AP (Jeju Island) conference. 75 organizations and businesses that came to the exhibition booth have shown a keen interest in collaborating with us. A prominent keynote speaker and more than 60 symposia, student and up-and-coming researcher programs, and various other exchange activities are open under the topic of the New Chapter of Future Regenerative Medicine. 1,200 individuals from 35 nations participated and attended. Through presentations of our U-FAB Activo, we have increased awareness and attracted partners by taking part in and attending the exhibition by a number of research institutes and researchers in the Asia-Pacific area that is relevant to regenerative medicine and pharmaceuticals. With 1,350 attendees from 33 countries, encompassing North America and Europe as well as the Asia-Pacific, the conference was the biggest among the regional academic conferences of the International Society for Organizational Engineering and Regeneration. Since its founding in 2005, the International Association of Organizational Engineering and Rehabilitation Medicine has organized academic conferences in three different continents each year: Asia-Pacific, Europe, and North America. Every three years, it also hosts a global conference. The Asia-Pacific Regional Conference took place in Daegu in 2014, while the World Congress took place in Seoul in 2009.

* June 13 (Monday) to June 15 (Wed) 2022 * San Diego Convention Center, San Diego, California, USA At the 2022 Bio International Convention-San Diego, Clecell Co., Ltd. (CEO Jeon Kyung-hwi, Lee Dong-hyuk) participated and unveiled the 3D bioprinter U-FAB ACTIVO. The largest bioindustry exhibition in the United States, Bio USA 2022, was attended by Clecell in June, showcasing the quality of Korean biotech technological advancement. "Bio USA" is a complete convention event hosted by the U.S. Bio Association, the largest bio-company association in the world, where major pharmaceutical firms from across the world (Big Pharma) and potential biotech startups can exhibit, organize seminars, and form technology investment alliances. The business forum, which serves as a venue for active technological and commercial interactions between bio-health firms, is anticipated to serve as a springboard for the development of business outcomes including technology transfer and the drawing of outside investment from numerous local and international businesses and embassies.

* Date: May 11th (Wed) - 13th (Fri) 2022 * Place: COEX - Seoul The Korea Health Industry Promotion Agency (CEO Kwon Soon-man, hereinafter the Promotion Agency) and Chungcheongbuk-do (Governor Lee Si-jong, hereinafter Chungcheongbuk-do) jointly hosted Bio Korea 2022 on May 11 at COEX in Seoul. The Ministry of Health and Welfare-sponsored Bio Korea 2022 (BIO KOREA 2022) was attended by CleCell Co., Ltd. (CEO Jeon Kyung-hwi, Lee Dong-hyuk), who also unveiled their 3D bioprinter U-FAB ACTIVO. The 2022 Bio Korea International Convention is a display of the most recent health-related innovations and goods. The conference brought together 150 bio-health specialists from 7 countries to discuss the newest market and technological developments across the sector in 21 sessions on 14 topics, including advanced treatment technology, digital health, and technology business. The business forum, which serves as a venue for frequent technological and commercial interactions among bio-health companies, is anticipated to mark the beginning of the development of business outcomes like technology transfer and investment attraction with the participation of numerous domestic and foreign businesses as well as foreign embassies.

* Time: 2022 Apr 27th - 29th * Location: National Assembly of South Korea The 3D bioprinter U-FAB ACTIVO was displayed by Clecell Co., Ltd. at the National Assembly exhibition "Save Ralph," which took place there for three days from April 27 (Wed) to 29 (Fri). The "Save Ralph" exhibition was held on the second floor of the National Assembly building on April 24 in observance of World Experimental Animals Day, which called for the Animal Alternative Test Act to be passed on April 27. Rep. Nam In-soon and Korea Humane Society International (HSI) organized the exhibition, which featured 23 lawmakers from both the ruling and opposition parties as co-hosts. The Ministry of Food and Drug Safety and the Osong Advanced Medical Industry Promotion Foundation also sponsored the event. At the show, we had the opportunity to personally examine animal replacement testing techniques including organ chips, human cell tests, and 3D printing testing techniques. Clecell Co., Ltd., who was in charge of the 3D printing test procedure at this event, installed U-FAB ACTIVO to highlight U-FAB ACTIVO.

KSSCR 2022 Winter Conference * Time : 2022 Jan 19th - 21st * Location : Sonovell Vivalty Park in Hongcheon-gun, Gangwon-do The 3D Bioprinter U-FAB ACTIVO was introduced by Clecell Co., Ltd. (CEO Jeon Kyung-hwi, Lee Dong-hyuk) during the Korea Stem Cell Society (KSSCR) 2022 Winter Academic Conference, which took place at Sonovell Vivalty Park in Hongcheon-gun, Gangwon-do for three days from January 19 (Wed) to 21 (Fri). The operation of the Advanced Regenerative Medicine and Advanced Biopharmaceuticals Review Committee was discussed in general at the 2022 Winter Academic Conference of the Korean Stem Cell Society (KSSCR). Attendees included representatives from corporations and academic research centers from almost 70 different nations. Clecell Co., Ltd. set up a booth at this event to highlight the U-FAB ACTIVO technology platform. looking for collaborations in commercialization, research, and development, etc.